TF and hypertensive disorder: In line with these findings, MSC-EVs were subsequently reported to reduce GS and/or TF in the settings of UUO [11, 28, 39, 41], hypertension [15, 23, 24, 45], and diabetic CKD [22, 25, 35]; where the damage was improved via mechanisms involving RNA or protein transfer.